Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER_GOV 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Hepatitis C, Chronic 2Carcinoma, Hepatocellular 2Recurrence 1

Interventions

Cisplatin 49Capecitabine 41apatinib 34Gemcitabine 33Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Surgical Procedures, Operative 17Nivolumab 17pembrolizumab 16Exercise 16Metformin 15camrelizumab 14S 1 (combination) 14Radiation 14Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11toripalimab 10Vinorelbine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × ledipasvir × Clear all
NCT02771405 2026-04-13

FRI-STC

National Hepatology & Tropical Medicine Research Institute

Phase 3 Completed
150 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hepatitis C, Chronic

NCT02959359 2017-08-07

DAA in the Risk of Recurrence After Curative Treatment of HCC

Taipei Veterans General Hospital, Taiwan

Phase 4 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡